IPP Bureau
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure
By IPP Bureau - September 02, 2024
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG
By IPP Bureau - September 02, 2024
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Govt. to improve availability of infrastructure and trained manpower for organ transplantation
By IPP Bureau - September 01, 2024
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment
By IPP Bureau - September 01, 2024
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Biocon Pharma receives USFDA approval for daptomycin
By IPP Bureau - September 01, 2024
The approval further adds to Biocon’s portfolio of complex drug products
Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility
By IPP Bureau - August 31, 2024
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
By IPP Bureau - August 31, 2024
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
DKSH partners with Hasten Biopharmaceutical’s growth in Thailand
By IPP Bureau - August 31, 2024
Indian doctor participates in Jordan’s first robotic radical hysterectomies
By IPP Bureau - August 31, 2024
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
By IPP Bureau - August 30, 2024
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
By IPP Bureau - August 30, 2024
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Natco Pharma announces submission of TABRECTA to USFDA
By IPP Bureau - August 30, 2024
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study
By IPP Bureau - August 30, 2024
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Suven Life Sciences announces FDA acceptance of investigational new drug
By IPP Bureau - August 30, 2024
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
